| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1023674042 |
| P356 | DOI | 10.1186/S13098-017-0204-6 |
| P932 | PMC publication ID | 5241936 |
| P698 | PubMed publication ID | 28115994 |
| P2093 | author name string | Antonio Pérez | |
| Inka Miñambres | |||
| P2860 | cites work | Lixisenatide as add-on therapy to basal insulin | Q27007547 |
| Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum | Q28117412 | ||
| Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study | Q28293505 | ||
| Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration | Q28378259 | ||
| Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). | Q33960291 | ||
| Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | Q34540403 | ||
| Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). | Q34986024 | ||
| Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes | Q35563643 | ||
| Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus | Q35824086 | ||
| Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control | Q35936644 | ||
| Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes | Q36050559 | ||
| Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). | Q36303786 | ||
| Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature | Q36872178 | ||
| Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes | Q36972891 | ||
| Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial | Q37105140 | ||
| Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). | Q37106467 | ||
| Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L) | Q37106537 | ||
| Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin | Q37119965 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). | Q37193446 | ||
| Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists | Q37340223 | ||
| Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing | Q37364896 | ||
| Combining basal insulin analogs with glucagon-like peptide-1 mimetics | Q37895271 | ||
| Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review | Q38028942 | ||
| GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus | Q38040314 | ||
| Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes | Q38083047 | ||
| Relationships between gastric emptying, postprandial glycemia, and incretin hormones | Q38101324 | ||
| Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus | Q38155273 | ||
| Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis | Q38249061 | ||
| Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome | Q41078909 | ||
| Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes | Q42165729 | ||
| Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial | Q42671884 | ||
| Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes | Q43025106 | ||
| Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia | Q43650443 | ||
| Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers | Q43913912 | ||
| Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). | Q44333619 | ||
| Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes | Q44526985 | ||
| Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial | Q44909518 | ||
| Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes | Q46448933 | ||
| Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. | Q48071098 | ||
| Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not contr | Q48226441 | ||
| Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). | Q48273566 | ||
| HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. | Q51321425 | ||
| Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. | Q51321430 | ||
| DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. | Q51379684 | ||
| Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. | Q51480316 | ||
| Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. | Q51743679 | ||
| Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining β-cell function and achievement of HbA1c target one year after initiation. | Q52924065 | ||
| The comparative study of acetyl-11-keto-beta-boswellic acid (AKBA) and aspirin in the prevention of intestinal adenomatous polyposis in APC(Min/+) mice. | Q53240629 | ||
| Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | Q57412648 | ||
| Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study | Q59624425 | ||
| Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes | Q59624449 | ||
| Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV | Q71940328 | ||
| GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro | Q73444367 | ||
| PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION | Q77059466 | ||
| A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON) | Q87130009 | ||
| Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials | Q87595911 | ||
| P304 | page(s) | 6 | |
| P577 | publication date | 2017-01-18 | |
| P1433 | published in | Diabetology and Metabolic Syndrome | Q15816649 |
| P1476 | title | Is there a justification for classifying GLP-1 receptor agonists as basal and prandial? | |
| P478 | volume | 9 |
| Q42380223 | Minimizing Glycemic Fluctuations in Patients with Type 2 Diabetes: Approaches and Importance | cites work | P2860 |
Search more.